CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services


CDC's Response to Ending Neglect


  1. CDC. 1989. A strategic plan for the elimination of tuberculosis in the United States. MMWR 1989;38 (Suppl S-3).
  2. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 55: 1595-1600.
  3. Cantwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 72: 535-39.
  4. CDC. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons Florida and New York, 1988-1991. MMWR 1991; 40: 585-91.
  5. CDC. National action plan to combat multidrug-resistant tuberculosis. MMWR 1992; 41 (RR-11).
  6. CDC. Reported Tuberculosis in the United States, 2000. Atlanta, GA: DHHS/CDC; August 2001.
  7. CDC. Reported Tuberculosis in the United States, 2001. Atlanta, GA: DHHS/CDC; 2001. Available Accessed July 2002.
  8. Miller B, Castro KG. Sharpen available tools for tuberculosis control, but new tools needed for elimination. JAMA 1996; 276: 1916-17.
  9. Talbot EA, Moore M, McCray E, Binkin NJ. Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA 2000; 284: 2894-2900.
  10. Goldberg BW. Managed care and public health departments: who is responsible for the health of the population? Annu Rev Public Health 1998; 19: 527-37.
  11. Institute of Medicine. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
  12. Kenyon TA, Valway SE, Ihle WW, Onorato IM, Castro KG. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med 1996; 334: 933-938.
  13. Kline SE, Hedemark LL, Davies SF. Outbreak of tuberculosis among regular patrons of a neighborhood bar. N Engl J Med 1995; 333 (4): 222-227.
  14. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City turning the tide. N Engl J Med 1995; 333 (4): 229-33.
  15. Alland D, Kalkut GE, Moss AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-16.
  16. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 33: 1703-9.
  17. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1229-30.
  18. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279: 943-8.
  19. McKenna MT, McCray E, Jones JL, Onorato IM, Castro KG. The fall after the rise: tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998; 88: 1059-63.
  20. Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG. Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999; 3: 272-80.
  21. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162: 2017-18.
  22. Reichler M, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287(8): 991-995.
  23. Halverson PK, Mays GP, Miler CA, Daluzny AD, Richards TB. Managed care and the public health challenge of TB. Public Health Reports 1997; 112: 22-8.
  24. Miller B, Rosenbaum S, Strange PV, Solomon SL, Castro KG. Tuberculosis control in a changing health care system: model contract specifications for managed care organizations. Clin Infect Dis 1998; 27: 677-86.
  25. Rutherford GW. Public health, communicable diseases, and managed care: will managed care improve or weaken communicable disease control? Am J Prev Med 1998; 14 (Suppl): 53-9.
  26. Crawford JT. New technologies in the diagnosis of tuberculosis. Semin Respir Infect 1994; 9: 62-70.
  27. American Thoracic Society (ATS). Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997; 155(5): 1804-14.
  28. World Health Organization. Framework for Effective Tuberculosis Control. Geneva: WHO; 1994.
  29. Drobniewski FA, Wilson SM. The rapid diagnosis of isoniazid and rifampin resistance in Mycobacterium tuberculosis a molecular story. J Med Microbiol 1998; 47: 189-96.
  30. Lyashchenko K, Colangeli R, Houde M. Al Jahdali H, Menzies D, Gennaro ML. Heterogeneous antibody responses in tuberculosis. Infect Immun 1998; 66: 3936-40.
  31. Samanich KM, Belisle JT, Sonnenberg MG, Keen MA, Zolla-Pazner S, Laal SJ. Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. Infect Dis 1998; 178: 1534-8.
  32. Streeton JA, Desem N, Jones SL. 1998. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998; 2: 443-50.
  33. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
  34. Behr MA, Small PM. Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician? Clin Infect Dis 1997; 25: 806-10.
  35. Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56: 607-16.
  36. CDC. Notice to readers: Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR 1998; 47: 911-12.
  37. O'Brien RJ, Vernon AA. New tuberculosis drug development. How can we do it better? Am J Respir Crit Care Med 1998; 157: 1705-7.
  38. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
  39. Ginsberg AM. A proposed national strategy for tuberculosis vaccine development. Clin Infect Dis 2000; 30 (Suppl 3): S233-S242.
  40. World Health Organization. The World Health Report: Making a Difference. Geneva: WHO; 1999: 116.
  41. Zuber PLF, McKenna MT, Binkin NJ, Onorato IM, Castro KG. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997; 278: 304-7.
  42. Netto EM, Dye C, Raviglione MC. Progress in global TB control 1995-96, with emphasis on 22 high-incidence countries. Int J Tuberc Lung Dis 1999; 3(4): 310-320.
  43. Cantwell MF, Binkin NJ. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis 1996; 77: 220-5.
  44. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. World Health Organization - Interrnational Union Against Tuberculosis and Lung Disease Working Group on Antituberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
  45. CDC. Tuberculosis morbidity United States, 1997. MMWR 1998; 47: 253-57.
  46. Cantwell MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998; 157: 1016-20.
  47. Binkin NJ, Vernon AA, Simone PM, et al. Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services. Int J Tuberc Lung Dis 1999; 3: 663-74.
  48. CDC. Tuberculosis control laws United States, 1993: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1993; 42 (RR-15).
  49. American Thoracic Society (ATS)/CDC. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-95.
  50. Chaulk CP, Grady M. Evaluating tuberculosis control programs: strategies, tools and models. Int J Tuberc Lung Dis 2000; 4 (Suppl): S55-S60.
  51. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997; 12: 63-70.
  52. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326: 231-5.
  53. Snider DE, Cauthen GM, Farer LS, et al. Drug-resistant tuberculosis. Am Rev Respir Dis 1991; 144: 732.
  54. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-671.
  55. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-837.
  56. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities, 1994. MMWR 1994; 43 (RR-13).
  57. CDC. Instructions to Panel Physicians for Completing Chest X-Ray and Classification Worksheet. Available at Accessed August 2002.
  58. CDC. Essential components of a tuberculosis prevention and control program: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1995; 44 (RR-11): 1-16.
  59. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-75.
  60. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities and next steps. Am J Respir Crit Care Med 2001; 163: 1055-1058.
  61. Datta M, Radhamani MP, Selvaraj R, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tuber Lung Dis 1993; 74: 180-6.
  62. CDC. Primary multidrug-resistant tuberculosis Ivanovo Oblast, Russia, 1999. MMWR 1999; 48: 661-3.
  63. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-91.
  64. World Health Organization. Preventive therapy against tuberculosis in people living with HIV. Weekly Epidemiol Rec 1999; 74: 385-98.
  65. CDC. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1998; 47 (RR-13): 1-6.
  66. CDC. Improving Tuberculosis Treatment and Control: An Agenda for Behavioral, Social, and Health Systems Research. Proceedings of Tuberculosis and Behavior: National Workshop on Research for the 21st Century; August 28-30, 1994, Bethesda, MD. Atlanta, GA: CDC;1995.
  67. DHHS. Making health communications programs work: planning guide. Washington, DC: DHHS; 1992.


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333